Can you provide more details on apotex's us filing for ruxolitinib?

Apotex's U.S. filing for ruxolitinib

Apotex has submitted an Abbreviated New Drug Application (ANDA) for ruxolitinib phosphate tablets to the FDA, seeking approval as a generic version of the reference product Jakafi. The filing targets the same strengths currently marketed by Incyte, but does not include any new clinical data or changes to the approved indications.

When can Apotex launch if the ANDA is approved?

Apotex must still resolve any patent disputes before it can market the product. The company has filed a Paragraph IV certification against one or more patents listed in the Orange Book for Jakafi, asserting that those patents are invalid, unenforceable, or not infringed. Incyte has the option to sue within 45 days of receiving notice, which would trigger a 30-month stay on final FDA approval.

Which patents is Apotex challenging?

Public records show Apotex targeting the key composition-of-matter and use patents that protect ruxolitinib. The earliest of these patents is set to expire in late 2028, with additional patents extending coverage into the 2030s. A successful challenge could allow Apotex to enter before the full patent term ends, though litigation outcomes remain uncertain.

How does Apotex's filing compare with other generic applicants?

Multiple companies, including Teva, Sun Pharma, and MSN Pharmaceuticals, have also filed ANDAs for ruxolitinib. Apotex's application is among the earlier ones, but first-to-file status and any 180-day exclusivity will depend on the order of submissions and litigation results. No company has yet received tentative approval.

What happens to pricing and patient access if generics launch?

Generic entry typically produces rapid price reductions. Analysts project initial discounts of 30-50% off Jakafi's list price, with deeper cuts possible once multiple generics are available. For myelofibrosis and polycythemia vera patients, lower-cost options could improve adherence, though payers may still require prior authorization or step therapy.

Has Apotex disclosed a settlement or licensing deal?

No public settlement has been announced. If Apotex and Incyte reach an agreement, it would likely include a licensed entry date after the 30-month stay but before patent expiry. Such deals are common in ruxolitinib litigation and can be tracked on DrugPatentWatch.com.